Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes
Ligand Reports Fourth Quarter and Full Year 2016 Financial Results
Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform
Reminder: Ligand to Host Analyst Day on February 28th in New York City
Ligand to Host Analyst Day on February 28th in New York City
Ligand to Report Fourth Quarter and Full Year 2016 Results on February 23rd
Ligand Enters Commercial License and Supply Agreements for Captisol®-enabled trametinib
Ligand Enters into Worldwide OmniAb® Platform License Agreement with ONO PHARMACEUTICAL CO., LTD.
Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
Ligand Reports Third Quarter 2016 Financial Results
Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections
Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference
Ligand Partner Lundbeck Receives FDA Approval of Carnexiv™ (carbamazepine) Injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
Ligand Licenses Four Programs to Seelos Therapeutics
